Adverse event assessment in prostate cancer patients receiving androgen deprivation therapy: are we doing enough?

Minerva Urol Nephrol. 2021 Dec;73(6):870-872. doi: 10.23736/S2724-6051.21.04817-5.

Authors

Fabio Turco¹, Marcello Tucci², Consuelo Buttigliero³

Affiliations

¹ Division of Medical Oncology, Department of Oncology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy.
² Department of Medical Oncology, Cardinal Massaia Hospital, Asti, Italy.
³ Division of Medical Oncology, Department of Oncology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy - consuelo.buttigliero@unito.it.

PMID: 35144376
DOI: 10.23736/S2724-6051.21.04817-5

No abstract available

MeSH terms

Androgen Antagonists* / adverse effects
Androgens / therapeutic use
Antineoplastic Agents, Hormonal / therapeutic use
Humans
Male
Prostatic Neoplasms* / drug therapy
Risk Factors

Substances

Androgen Antagonists
Androgens
Antineoplastic Agents, Hormonal